Press releases

2019  |  2018  |  All
August 1, 2019
Compass Therapeutics Appoints Julie Sunderland to Board of Directors
July 8, 2019
Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471
June 17, 2019
Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471

Presentations and publications

View all
April 10, 2019 | Keystone Symposia Conference: “D2: Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies”
Novel class of NK engagers targeting NKp30 selected from unbiased screen of common light chain based bispecific antibodies
April 9, 2019 | Keystone Symposia Conference: “D2: Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies”
A versatile platform for efficient affinity optimization of common light chain multi-specific antibodies
March 25, 2019 | AACR Annual Meeting 2019
Preclinical characterization of NKp30xBCMA, a novel class of NK‐Cell Engagers

In the news

View all
October 2, 2018
FierceBiotech’s 2018 Fierce 15
July 13, 2018
Compass Therapeutics raises $130 million to develop I-O candidate
July 12, 2018
Compass Therapeutics eyes possible IPO after $132M investment

Events

The Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
November 6 – 10
National Harbor, Maryland
2019 ACR/ARP Annual Meeting
November 8 – 13
Atlanta, Georgia
PEGS Europe 2019
November 18 – 22
Lisbon, Portugal
61st ASH Annual Meeting & Exposition
December 7 – 10
Orlando, FL